WO2019218076A1 - Dynamic angiographic imaging - Google Patents
Dynamic angiographic imaging Download PDFInfo
- Publication number
- WO2019218076A1 WO2019218076A1 PCT/CA2019/050668 CA2019050668W WO2019218076A1 WO 2019218076 A1 WO2019218076 A1 WO 2019218076A1 CA 2019050668 W CA2019050668 W CA 2019050668W WO 2019218076 A1 WO2019218076 A1 WO 2019218076A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- time
- blood flow
- enhancement
- enhancement curve
- curve
- Prior art date
Links
- 238000003384 imaging method Methods 0.000 title claims abstract description 70
- 230000017531 blood circulation Effects 0.000 claims abstract description 132
- 238000000034 method Methods 0.000 claims abstract description 105
- 239000002872 contrast media Substances 0.000 claims abstract description 96
- 210000004204 blood vessel Anatomy 0.000 claims abstract description 88
- 230000007423 decrease Effects 0.000 claims abstract description 35
- 238000005070 sampling Methods 0.000 claims description 77
- 238000002591 computed tomography Methods 0.000 claims description 53
- 238000002595 magnetic resonance imaging Methods 0.000 claims description 16
- 238000011144 upstream manufacturing Methods 0.000 claims description 15
- 230000004075 alteration Effects 0.000 claims description 13
- 230000008859 change Effects 0.000 claims description 9
- 210000004351 coronary vessel Anatomy 0.000 description 49
- 208000031481 Pathologic Constriction Diseases 0.000 description 45
- 208000037804 stenosis Diseases 0.000 description 45
- 210000001367 artery Anatomy 0.000 description 41
- 230000036262 stenosis Effects 0.000 description 31
- 210000002216 heart Anatomy 0.000 description 26
- 238000004458 analytical method Methods 0.000 description 23
- 238000005259 measurement Methods 0.000 description 22
- 239000008280 blood Substances 0.000 description 21
- 210000004369 blood Anatomy 0.000 description 21
- 230000033001 locomotion Effects 0.000 description 21
- 238000002347 injection Methods 0.000 description 20
- 239000007924 injection Substances 0.000 description 20
- 230000000544 hyperemic effect Effects 0.000 description 18
- 230000000295 complement effect Effects 0.000 description 17
- 230000010412 perfusion Effects 0.000 description 16
- 210000000709 aorta Anatomy 0.000 description 15
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 12
- 238000012937 correction Methods 0.000 description 12
- 101000666730 Homo sapiens T-complex protein 1 subunit alpha Proteins 0.000 description 11
- 102100038410 T-complex protein 1 subunit alpha Human genes 0.000 description 11
- 238000004364 calculation method Methods 0.000 description 10
- 238000002586 coronary angiography Methods 0.000 description 10
- 230000002107 myocardial effect Effects 0.000 description 10
- 210000002620 vena cava superior Anatomy 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 230000005855 radiation Effects 0.000 description 9
- 208000029078 coronary artery disease Diseases 0.000 description 8
- 238000010586 diagram Methods 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 8
- 238000004590 computer program Methods 0.000 description 7
- 238000012067 mathematical method Methods 0.000 description 7
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 6
- 229960005305 adenosine Drugs 0.000 description 6
- 230000000747 cardiac effect Effects 0.000 description 6
- 238000001990 intravenous administration Methods 0.000 description 6
- 210000004165 myocardium Anatomy 0.000 description 6
- 239000000700 radioactive tracer Substances 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 210000003462 vein Anatomy 0.000 description 6
- 230000004087 circulation Effects 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 230000002093 peripheral effect Effects 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 230000000304 vasodilatating effect Effects 0.000 description 5
- 230000024883 vasodilation Effects 0.000 description 5
- 229940124549 vasodilator Drugs 0.000 description 5
- 239000003071 vasodilator agent Substances 0.000 description 5
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 4
- 201000000057 Coronary Stenosis Diseases 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 238000004891 communication Methods 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 238000010191 image analysis Methods 0.000 description 4
- 229910052740 iodine Inorganic materials 0.000 description 4
- 239000011630 iodine Substances 0.000 description 4
- 208000028867 ischemia Diseases 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 238000005381 potential energy Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000000284 resting effect Effects 0.000 description 4
- 238000012552 review Methods 0.000 description 4
- 238000002603 single-photon emission computed tomography Methods 0.000 description 4
- 230000035488 systolic blood pressure Effects 0.000 description 4
- 229910052688 Gadolinium Inorganic materials 0.000 description 3
- 208000012322 Raynaud phenomenon Diseases 0.000 description 3
- 230000004872 arterial blood pressure Effects 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229940039231 contrast media Drugs 0.000 description 3
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 3
- 229960002768 dipyridamole Drugs 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000001360 synchronised effect Effects 0.000 description 3
- 230000009897 systematic effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 206010011089 Coronary artery stenosis Diseases 0.000 description 2
- 208000003782 Raynaud disease Diseases 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 230000004308 accommodation Effects 0.000 description 2
- 210000003484 anatomy Anatomy 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000010968 computed tomography angiography Methods 0.000 description 2
- 238000013170 computed tomography imaging Methods 0.000 description 2
- 238000013500 data storage Methods 0.000 description 2
- 238000002059 diagnostic imaging Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002594 fluoroscopy Methods 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 210000005166 vasculature Anatomy 0.000 description 2
- 206010002329 Aneurysm Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010059245 Angiopathy Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000014882 Carotid artery disease Diseases 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 206010014523 Embolism and thrombosis Diseases 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010025282 Lymphoedema Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 241000042032 Petrocephalus catostoma Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010043540 Thromboangiitis obliterans Diseases 0.000 description 1
- 206010046996 Varicose vein Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 210000002376 aorta thoracic Anatomy 0.000 description 1
- 210000001765 aortic valve Anatomy 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000009530 blood pressure measurement Methods 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 210000005242 cardiac chamber Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 238000002247 constant time method Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- XEYBHCRIKKKOSS-UHFFFAOYSA-N disodium;azanylidyneoxidanium;iron(2+);pentacyanide Chemical compound [Na+].[Na+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].[O+]#N XEYBHCRIKKKOSS-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 208000002502 lymphedema Diseases 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 208000030613 peripheral artery disease Diseases 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 238000012805 post-processing Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 229960003614 regadenoson Drugs 0.000 description 1
- LZPZPHGJDAGEJZ-AKAIJSEGSA-N regadenoson Chemical compound C1=C(C(=O)NC)C=NN1C1=NC(N)=C(N=CN2[C@H]3[C@@H]([C@H](O)[C@@H](CO)O3)O)C2=N1 LZPZPHGJDAGEJZ-AKAIJSEGSA-N 0.000 description 1
- 208000015670 renal artery disease Diseases 0.000 description 1
- 230000011218 segmentation Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940083618 sodium nitroprusside Drugs 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 208000027185 varicose disease Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 208000037997 venous disease Diseases 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
- A61B5/026—Measuring blood flow
- A61B5/0275—Measuring blood flow using tracers, e.g. dye dilution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
- A61B5/026—Measuring blood flow
- A61B5/0263—Measuring blood flow using NMR
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
- A61B6/03—Computed tomography [CT]
- A61B6/032—Transmission computed tomography [CT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/48—Diagnostic techniques
- A61B6/481—Diagnostic techniques involving the use of contrast agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/50—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications
- A61B6/504—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications for diagnosis of blood vessels, e.g. by angiography
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/52—Devices using data or image processing specially adapted for radiation diagnosis
- A61B6/5211—Devices using data or image processing specially adapted for radiation diagnosis involving processing of medical diagnostic data
- A61B6/5217—Devices using data or image processing specially adapted for radiation diagnosis involving processing of medical diagnostic data extracting a diagnostic or physiological parameter from medical diagnostic data
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
- G01R33/00—Arrangements or instruments for measuring magnetic variables
- G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
- G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
- G01R33/48—NMR imaging systems
- G01R33/54—Signal processing systems, e.g. using pulse sequences ; Generation or control of pulse sequences; Operator console
- G01R33/56—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution
- G01R33/563—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution of moving material, e.g. flow contrast angiography
- G01R33/56308—Characterization of motion or flow; Dynamic imaging
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
- G01R33/00—Arrangements or instruments for measuring magnetic variables
- G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
- G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
- G01R33/48—NMR imaging systems
- G01R33/54—Signal processing systems, e.g. using pulse sequences ; Generation or control of pulse sequences; Operator console
- G01R33/56—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution
- G01R33/563—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution of moving material, e.g. flow contrast angiography
- G01R33/5635—Angiography, e.g. contrast-enhanced angiography [CE-MRA] or time-of-flight angiography [TOF-MRA]
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/40—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H30/00—ICT specially adapted for the handling or processing of medical images
- G16H30/20—ICT specially adapted for the handling or processing of medical images for handling medical images, e.g. DICOM, HL7 or PACS
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H30/00—ICT specially adapted for the handling or processing of medical images
- G16H30/40—ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/50—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
Definitions
- a system for dynamic angiographic imaging comprising: a memory for storing image data comprising a plurality of corresponding images capturing at least a portion of both an increase phase and a decline phase of a contrast agent in a blood vessel of interest;
- a processor configured to generate at least one time-enhancement curve of the contrast agent based on the image data, the time-enhancement curve having an upslope and a downslope; and to determine a blood flow characteristic in the blood vessel of interest based on the time-enhancement curve.
- Figure 1 shows a schematic of a dynamic angiographic imaging (DAI) system.
- DAI dynamic angiographic imaging
- Figure 6 shows a flow diagram of determining a blood flow characteristic based on the TEC in the DAI method shown in Figure 2.
- Figure 7 shows a flow diagram of a variant DAI method.
- Figure 17 shows ((a) and (b)) contrast-enhanced heart images at the two slices where time- enhancement curves in the left main (LM) artery and left anterior descending (LAD) artery were measured; ((c) to (e)) reformatted lumen view of the LM and LAD with the location of each ROI and the corresponding lumen diameter labelled; (f) three-dimensional rendered image of the heart with the approximate location of each ROI labelled.
- LM left main
- LAD left anterior descending
- Figure 22 shows ((a) and (b)) curve-reformatted view of the LAD with the plaque composition shown; (c) cross-sectional view of the LAD with the plaque composition shown; ((d) to (f)) reformatted lumen view of the LAD with the location of the pre-stenosis, in-stenosis and post-stenosis segments and the corresponding lumen diameters shown.
- Figure 26 shows ((a), (b) and (c)) a stent obstruction in LCx for patient #4, and pre- and post-stent time-enhancement curves generated from scan data acquired during (d) non-hyperemic or rest condition and (e) hyperemic stress condition.
- Figure 29 shows ((a) to (f)) time-ordered images of RCA of a pig acquired using invasive coronary angiography, and plots of (g) contrast signal intensity versus frame number and (h) time- enhancement curve.
- Figure 30 shows MRI tomographic slices of (a) RCA and (b) LAD of a pig, and ((c) to (n)) time-ordered Gadolinium -based Tl -weighted images of RCA (same slice location as (a)).
- DAI dynamic angiographic imaging
- FIG. 1 shows a computer implemented imaging system, more specifically an example of a DAI system 2, incorporating a computed tomography (CT) scanner 4.
- CT scanner 4 may be any mutli-row or multi-slice CT scanner typically comprising a radiation source, a radiation detector and an adjustable, often motorized, support or table for maintaining a subject in a desired position (for example, a prone or supine position) during a scan procedure.
- the radiation source generates radiation that traverses one or more predetermined sampling sites targeting a blood vessel of interest in the subject in synchronization with a contrast agent (also referred to as a tracer) administered to the subject.
- a contrast agent also referred to as a tracer
- Coronary blood flow is measured using the indicator-dilution principle, which indicates the degree of which tracer molecules (CT contrast media) mixed with blood after a bolus injection is dependent on the volumetric flow rate of blood. Mathematically, it can be expressed as:
- P A and P B are the coronary flow pressure (in Pascal or Pa) in slice A and B respectively
- p is the density of blood (g/cm )
- g is the Earth’s gravity (980 cm/s )
- h and h B are the relative height (in cm) above or below a reference plane from the center point in slice A and B
- P B is the pressure (energy) loss due to friction and/or turbulence (see Eq. 4).
- a plane that passes through center A can be chosen as the reference plane so that h A is always zero and the potential energy term associated with slice A (pgl ) can be omitted from Eq. 3 for simplicity. It should be noted that h B is positive if center B is above center A, and vice versa.
- the magnitude of PLF can be estimated using the Darcy-Weishbach equation:
- Re is the Reynolds number that predicts the flow behavior (laminar versus turbulent flow)
- e is the roughness metric which describes the surface texture of the pipe where the fluid flows. Blood vessels are assumed to be smooth pipes and hence s is zero.
- the Reynolds number is given by:
- Eq. (9) is also known as the Colebrook equation.
- the choice of Eq. (8) or (9) depends on the flow behavior (laminar versus turbulent), which can be estimated using the Reynolds number obtained from Eq. (7). In general, blood flow is fully laminar when Re ⁇ 2000 and fully turbulent when Re >4000.
- the magnitude of PLE in Eq. (4) can be estimated as:
- the wall shear stress is the shearing force exerted to the arterial wall surface by blood flow. This parameter may be useful for predicting the vulnerability of a plaque developed on the wall surface of an artery. Blood moves in parallel layers in a blood vessel due to its laminar behavior, with the flow velocity equaling zero at the surface of the vessel wall. Shear rate describes the rate at which different blood layers move past each other, and the wall shear rate specifically refers to the rate at which a blood layer of interest moves relative to the blood layer at the wall surface that has a zero velocity.
- This section presents a Complement step where information present in the dynamic perfusion images can be used to estimate the mass of tracers in the coronary system. Using patient- specific information may allow a more accurate measurement of coronary flow and pressure for individual patients.
- blood flow in the coronary arteries is at maximum during diastole rather than systole.
- the left ventricle continues to relax, leading to a substantial decrease in the aortic pressure and backflow in the aorta.
- a backflow eg., backward-propagating suction
- the backflow in the aorta together with the decrease in coronary resistance leads to the maximal coronary blood flow at diastole.
- Fi and F 2 are the volumetric flow rate (in mL/s) in slice 1 and 2 respectively
- Qi and Q 2 are the mass of tracers (in mg) in slice 1 and 2 respectively
- the integral of C ai (u) and C a2 (u) are the area under the time-enhancement curves measured in slice 1 and 2, respectively, from time 0 to t.
- Eq. (14) describes the fraction of tracers in slice 1 with respect to that in slice 2. Since some tracers passing through slice 2 enter the coronary arteries before reaching slice 1, Qi should be smaller than Q 2 . As blood flow in the heart is about 5% of the cardiac output, roughly 5% of the tracers leaving the heart should end up in the coronary circulation. If the tracers ejected from the heart are uniformly distributed along the aorta, QI/Q 2 should be approximately equal to 0.95 (Qi is about 95% of Q 2 . See experimental testing examples).
- Method Complement Step 2 in Figure 8 estimation of the mass of tracers in individual coronary arteries. Similar to mathematical treatment of Complement Step 1 in Figure 8, this section describes a method for the estimation of the mass of tracers in each epicardial coronary artery based on the information present in the dynamic perfusion images.
- a graphical representation of the coronary artery system can facilitate a description of Complement Step 2.
- the vasculature in any organ, such as the coronary artery system in the heart can be represented by a graph with multiple edges and vertices such as shown in Fig. 13.
- a vertex (v) can be viewed as the intersection connecting two (or more) blood vessels together, whereas an edge (E) can be viewed as the blood vessel that connects two vertices together.
- the graph shown in Fig. 12 can be expressed as:
- This graph is a directed graph in which the net flow in each edge is one direction only (not bi- directional). The flow usually moves in the direction away from the source (the aorta as represented by the dark grey cylinder in the graph).
- Each edge is assigned a number (as specified in Table 2) according to the American Heart Association model for the coronary arteries:
- n is the edge number.
- the fraction of tracers going from edge 5 (LM) to edge 6 (LAD) can be calculated by taking the ratio of Q 6 and Qs
- Eq. (18) equals the fraction of tracer distribution in the LAD with respect to the LM.
- the time point that corresponds to the maximum contrast enhancement in a coronary artery is first identified. It is used as the reference time point to track the position of the same artery at all the other time points.
- the search area in criteria#5 extends to one adjacent slice above (upstream) and an adjacent slice below (downstream) at the corresponding time point (a scan can capture 3D image data of all or part of a blood vessel, and the 3D image data can be divided into multiple slices so that an adjacent slice above (upstream) and an adjacent slice below (downstream) is readily available to compensate for an artery of interest missing at the time point). If the artery remains missing or is substantially blurred as a result of severe motion, linear interpolation is applied to estimate the missing contrast enhancement value in that section of the artery for that time point of the time-enhancement curve.
- FIG. l6a and l6b show the contrast-enhanced image of the heart acquired at rest and during maximal vasodilatory stress , respectively, at the slice location where the left main artery was seen.
- the time-enhancement curves measured from the left main artery before the bifurcation are shown in Fig. l6c.
- FIG. l7a and l7b show the contrast-enhanced heart images at two axial slices to illustrate where the TEC was measured in the left main (LM, ROI 1) and proximal (ROI 2) and distal (ROI 3) LAD.
- the slice locations were 60 mm apart.
- Figs. l7c, l7d and l7e show the reformatted lumen view of the LAD to illustrate the location of each ROI shown in Fig l7a and l7b.
- the lumen diameter at each location was also labelled.
- Fig. l7f shows the three-dimensional rendered image of the heart with the approximate location of each ROI.
- Experimental Example 3 The results of Experimental Example 3 are related to the use of mathematical methods described in Examples 1-4 from Fig. 8.
- the shear stress in the pre-stenosis, in-stenosis and post-stenosis segments of the LAD were estimated to be 0.047, 19.68 and 0.33 kPa respectively.
- the area under the curve (AUC) for the pre-stenosis, in stenosis and post-stenosis segments of the LAD were 2592.79, 2128.44 and 1711.38 HU-s respectively;
- the corresponding peak contrast enhancement in the same segments were 254.1, 146.1 and 193.2 HU respectively;
- the corresponding rate of change of the AUC in these segments in the wash-in phase were 20.2, 8.7 and 8.3 HU-s respectively.
- the AUC at slice 1 was 5.6% smaller than the AUC at slice 2. The result is comparable to the expected value ( ⁇ 5%) as explained in Mathematical Analysis of Complement Step 1 described above, which indicated that Complement Step 1 can be used to estimate the fraction of tracers going to the coronary system from the aorta.
- Fig. 24a and 24b show the left coronary arteries of patient #2 (same patient as in Experimental Example 2).
- the LM bifurcates into the LCx and LAD only, but the LM of this patient trifurcates into the intermediate branch (ramus) in addition to the LCx and LAD.
- the radius of each vessel and the corresponding maximum contrast enhancement are provided in Table 5.
- the product of radius squared and maximum contrast enhancement (values in the second last column in Table 5) of the parent vessel (LM) should equal the sum of the product of each daughter vessel (LCx, LAD and Ramus). Our finding showed that this is the case - there was only a 2.85% difference between these values (4890.73 vs. 5032.29).
- Experimental Example 6 The results of Experimental Example 6 illustrate use of time-enhancement curves to assess blood flow without requiring mathematical methods described in Examples 1-4 from Fig. 8, compare non-hyperemic versus hyperemic stress during scan acquisition, and illustrate additional metrics (ie., in addition to those shown in Fig. 8) derived from time-enhancement curve for functional assessment of blood flow.
- the metrics described in (3) measured at rest may be sufficient for functional CAD assessment, implying that hyperemic stress of the patient with drug may not be required.
- Figure 25 shows the right coronary artery (RCA) with two calcified plaques close to each other in the proximal segment (white arrows in (a) and (b)).
- the calcium on each side within the lumen affects the measurement of the lumen diameter, which is the information required for the current FFR-CT methods that are based on computational fluid dynamics.
- the dotted light-grey arrows and the solid dark-grey arrows in (a) and (b) show the locations at which the pre-plaque (upstream) and post-plaque (downstream) time-enhancement curves were sampled.
- the circles represent the measured enhancement at different time points in the pre-plaque position at rest and during maximal vasodilatory stress, respectively.
- the dotted light- grey curves in these graphs represent the corresponding fitted time-enhancement curves.
- the squares in (c) and (d) are the measured enhancement at different time points in the post-plaque position at rest and stress, respectively.
- the corresponding fitted time-enhancement curves are shown as the solid dark-grey curves in these graphs.
- the obtuse marginal (OM) branch of the left circumflex (LCx) artery shown in Figure 26 had an implanted stent in the proximal segment.
- the time-enhancement curves measured upstream (dotted light-grey arrows in (a) to (c)) and downstream (solid dark-grey arrows in (a) to (c)) to the stent are shown in the graphs in (d) and (e).
- the reformatted view of the OM artery (c) shows that the lumen visualization was significantly affected by the blooming artifacts, with the middle part of the stent seen to be completely blocked.
- the time-enhancement curve acquired after (downstream) the stent at rest shows that the stented lumen was narrowed but not completely blocked because there was passage of contrast at that sampling site.
- the post-stent AUC was considerably smaller compared to the pre-stent AUC, indicating that the coronary blood flow after the stent was faster than before the stent due to a narrower stented lumen as depicted by the Bernoulli’s equation.
- the pre-stent AUC at stress (dotted light-grey plot with circle markers in (e)) was much smaller compared to the pre-stent AUC at rest (dotted light-grey plot in (d)), while the post-stent AUC at stress (solid dark-grey plot with square markers in (e)) was minimally reduced from that at rest (solid dark-grey plot in (d)).
- the finding shows that there was a large increase in coronary blood flow in the segment prior to the stent at stress due to maximal vasodilation, but the increase in blood flow after the stent was minimal due to absence of or minimal vasodilation. It is therefore possible that the stenosis within the stent was functionally significant.
- the left anterior descending artery (LAD) shown in Figure 27 had multiple lesions.
- the proximal segment had complex calcified and non-calcified plaques (white arrows in (a) to (c); the middle segment had a stent implanted.
- the dotted light-grey and solid dark-grey arrows in (a) to (c) denote the locations where the pre-plaque and post-plaque time-enhancement curves were measured.
- the pre- (circle markers) and post-plaque (square markers) time-enhancement curves measured at rest and stress are shown in (d) and (e), respectively.
- the plaque in the proximal LAD resulted in a larger degree of lumen narrowing as reflected by a larger decrease in the AUC across the plaque at rest.
- the plaque in the proximal LAD may not be as functionally significant as the stenosed stent in the LCx ( Figure
- Metrics of blood flow, flow pressure, FFR and shear stress have been exemplified in Experimental Examples 1-3. Additional metrics derived from time-enhancement curves can be used for functional assessment of coronary stenosis.
- the time-enhancement curves shown in Figures 25 and 26 can be used to illustrate the additional metrics.
- the appearance of a time-enhancement curve can be quantitatively described using the following examples of additional metrics: area under curve (AUC), peak enhancement (PE), upslope, downslope, skewness, kurtosis.
- Skewness describes the asymmetry of the curve and its value ranges from -1 to +1.
- a zero skewness means the curve is perfectly symmetrical on both sides (upslope side compared to downslope side).
- a negative skewness implies the curve has a longer tail on the left (upslope) side than the right (downslope) side, whereas a positive skewness means the curve has a longer tail on the right (downslope) side than the left (upslope) side.
- kurtosis describes the sharpness of the curve. The normal value of kurtosis is 3. If the kurtosis is less than 3, the curve is flatter than normal, whereas a kurtosis greater than 3 implies the curve has a higher peak than normal.
- Table 6 summarizes the metrics for the RCA pre- and post-plaque curves at rest. The difference in each metric between the pre- and post-plaque curves is given by the subtraction of the two metrics (post - pre) and the ratio of the two metrics (post divided by pre).
- Experimental Example 7 The results of Experimental Example 7 illustrate accommodation of imaging modalities other than CT in the DAI method and system. More specifically, Example 7 shows the DAI method and system incorporating invasive coronary angiography as the imaging technology.
- x-ray dye iodinated contrast agent
- catheter selective angiography
- the passage of contrast solution in an artery leads to decrease in signal intensity in the blood vessel (the x-ray dye appears as dark colour as opposed to bright colour in a CT angiographic or CT perfusion source image).
- the first-pass of contrast agent in the LAD artery is shown in (a) to (f).
- Figure 29 shows another example acquired from the same pig as shown in Figure 28 to illustrate the proposed method can be applied to any artery of interest in selective coronary angiography.
- contrast agent was injected directly into the right coronary artery (RCA) at the orifice.
- Images in (a) to (f) show the first pass circulation of contrast in the RCA over a short period of time.
- the data in (g) shows the pixel intensities measured from the motion-corrected RCA at the sampling site denoted by the white arrows in (a) to (f), and the corresponding coronary time-enhancement curve is shown as the dotted line in (h).
- Experimental Example 8 The results of Experimental Example 8 illustrate accommodation of imaging modalities other than CT in the DAI method and system. More specifically, Example 8 shows the DAI method and system incorporating MRI as the imaging technology. Gadolinium -based Tl -weighted MR myocardial perfusion imaging.
- Figure 30 shows the images acquired from a MRI study on the same pig in Figure 28 and 29. Images shown in Figure 30 (a) and (b) were acquired in a supine scanning position similar to the scanning position for clinical CT and MRI studies. These images collectively illustrate that the coronary arteries such as the RCA and LAD can be seen in different tomographic slice locations in the transaxial view. The ascending aorta can also be seen in each slice for comparison.
- the images displayed in Figure 30 (c) to (n) are the Tl-weighted images acquired at the same slice location as in (a) following a bolus injection of Gadolinium -based contrast agent. It is clear that the circulation of contrast in the pulmonary blood vessels can be seen at the beginning, immediately followed by the circulation of contrast in the ascending aorta and coronary arteries (RCA). The wash-out of contrast can be seen at the end of the image series. To avoid signal saturation, a low dose of contrast was used in (about 1 mmole per 20 kg body weight) at an injection rate of 2.5 mL/s followed by saline flush. The imaging was ECG triggered and one frame was acquired per heart-beat. Since the arrival of contrast changes the signal intensity in the voxels within the arteries, we can obtain coronary time-enhancement curves in a similar fashion to CT and invasive coronary angiography and provide a functional assessment as in previous Experimental Examples.
- DAI dynamic angiographic imaging
- the DAI method 20 as shown Figure 2 is merely illustrative, and should not be considered as limiting to the DAI method as one or more steps shown in Figure 2 can be substituted or removed as desired for a specific implementation.
- CT scanning of a subject may be geographically or temporally displaced from image reconstruction.
- Figure 7 shows an example, of a variant DAI method 20a in which both projection data from CT scanning and image reconstruction occur at a prior stage and reconstructed images are stored for analysis at either a later date or for analysis by a third party.
- the variant DAI method 20a can initiate by obtaining 60a the stored image data.
- Contrast agent signal data can then be extracted 74a from the stored image data, optionally without explicitly identifying a target blood vessel in the image data.
- a time-enhancement curve is generated 76 based on the contrast agent signal data, the time-enhancement curve having an upslope plotted from data points obtained during an increase phase of the contrast agent signal data, and a downslope plotted from data points obtained during a decline phase of the contrast agent signal data.
- An FFR value is then determined according to the same method steps shown in Figure 6.
- the DAI method and system are not limited to computed tomography (CT) scanning, and can readily be adapted to other imaging modalities that have sufficient spatial resolution to image blood vessels, including MRI and other X-ray imaging techniques (ie., X-ray imaging techniques other than CT imaging), including for example fluoroscopy.
- CT computed tomography
- X-ray based scans are a form of medical imaging comprising transmission of a high frequency electromagnetic signal that becomes attenuated as it passes through the body of a subject with the remaining signal captured by a detector for subsequent analysis.
- MRI Magnetic Resonance Imaging
- MRI scans involve the application of a magnetic field to a patient and the transmission of radio frequency pulses. Resonance energy is emitted by the patient and picked up by a receiver/detector that captures scan data for subsequent analysis.
- both X- ray scans and MRI scans involve the oral or intravenous administration of a contrast agent to a patient.
- Contrast agents for X-ray imaging techniques include for example iodine-based contrast agents.
- Contrast agent for MRI imaging techniques include for example galodinium-based contrast agents.
- Scan data acquired from X-ray based scanner devices/systems are often referenced as scan data or projection data interchangeably, while scan data acquired from MRI scanner devices/systems are typically referenced as scan data.
- scan data is understood to encompass the term projection data.
- Contrast agents also referred to as tracers
- the DAI method and system may accommodate any suitable combination of contrast agent and imaging modality provided that the imaging modality affords sufficient spatial resolution to image a blood vessel of interest or a portion of a blood vessel of interest.
- the elapsed time of an imaging scan procedure can be varied as desired provided that the imaging scan captures at least a portion of both an increase phase and a decline phase of contrast agent at the sampling site so as to obtain sufficient data to estimate shape of the time-enhancement curve.
- an imaging scan of greater than 5 seconds is needed.
- imaging scans can be configured to capture scan data for greater than 6 seconds, greater than 7 seconds, greater than 8 seconds, greater than 9 seconds or greater than 10 seconds.
- the number of images (also referred to as frames or individual scans) analyzed to generate the time-enhancement curve can be varied as desired provided that the number of images cumulatively captures at least a portion of both an increase phase and a decline phase of contrast agent at the sampling site so as to obtain sufficient data to estimate shape of the time-enhancement curve.
- an imaging scans of greater than 5 images is needed.
- imaging scans can be configured to capture scan data for greater than 6 images, greater than 8 images, greater than 10 images, greater than 12 images, greater than 14 images, greater than 16 images, greater than 18 images, or greater than 20 images.
- imaging scans configured to capture at least 10 images are observed to benefit consistency of peak value determinations and curve shape; signal intensity values need not be extracted from all of the at least 10 images, but the at least 10 images often provides a large enough set of images to select a subset of appropriate time-distributed images (typically 5 or more images) that leads to consistency of estimating curve shape.
- the DAI method and system is considered dynamic due to analysis of a plurality of images as distinguished from static techniques that evaluate a single image.
- Most commercially available CT angiography techniques are static.
- commercially available CT angiography techniques that are minimally dynamic (evaluating 2 to 3 images) do not recognize or consider benefits of acquiring scan data from both the increase phase and decline phase of contrast agent transit or generating a time-enhancement curve having an upslope, peak and downslope.
- a plurality of images, for example at least 5 images, for generating a time-enhancement curve are considered to be a plurality of corresponding images with the correspondence of images referring to a time-ordered sequence of multiple images located in the same sampling site or slice or in a group of adjacent sampling sites or slices (for example, consideration of adjacent sampling sites can occur in motion correction as described above for Complement Step 3 in Figure 8).
- correspondence of images is spatially limited to a single sampling site or a group of adjacent sampling sites, and correspondence of images does not include sampling sites spatially separated to be upstream versus downstream of a source of blood flow aberration.
- the first time-enhancement curve may be generated from a first plurality (or set) of corresponding images from a first sampling site located upstream of a suspected source of a blood flow aberration and the second time-enhancement curve may be generated from a second plurality (or set) of corresponding images from a second sampling site located downstream of the suspected source of the blood flow aberration.
- the first set of corresponding images will not be intermingled with the second set of corresponding images as the first and second sampling sites are spatially separated by an intervening suspected source of blood flow aberration.
- a first set of corresponding images from a first sampling site may be intermingled in a time-specific manner (so as to maintain a time-ordered sequence in the resulting intermingled set of corresponding images) with a second set of corresponding images from a second sampling site when the first and second sampling sites (slices) are abuttingly adjacent or close to abuttingly adjacent so as to minimize blood flow differences between the first and second sampling sites.
- Each set or plurality of corresponding images is time-ordered or time-resolved to generate a time-enhancement curve.
- the time-enhancement curve has an upslope, a peak and a downslope.
- Time-ordering is needed to generate the time-enhancement curve so that the upslope of the time enhancement curve is interpolated from time-specific contrast agent signal data points acquired during an increase phase of contrast agent transit, and the downslope of the time enhancement curve is interpolated from time-specific contrast agent signal data points acquired during a decline phase of contrast agent transit. Accordingly, acquisition of scan data and reconstruction of image data occurs with reference to a time-ordering scheme such that each set of corresponding images obtained from the image data can be arranged in a time-ordered sequence.
- a time-ordering scheme can be any convenient scheme including a time stamp with a real-time identifier, a relative-time identifier such as elapsed time from bolus injection, or any customized time identifier that can be used for identifying absolute or relative time of each image and time-resolved sequencing of the set of corresponding images.
- Established protocols for time intervals between contrast agent administration and image acquisition may be adopted in devising a time ordering scheme.
- established timing techniques for example bolus tracking, may be adopted to optimize timing of scan acquisition and time-ordering of image data.
- a contrast agent transit such as prior to entry, entry, wash-in, increase phase, decline phase, wash-out, clearance and subsequent to clearance, are referenced to a bolus injection event or more generally a contrast agent administration event, such that each of these terms, except prior to entry, describing a portion of a contrast agent transit that occurs subsequent to an associated injection or administration event.
- the term prior to entry may correspond to a time range that may begin earlier than the injection or administration event.
- the DAI method and system includes generation of at least one time- enhancement curve.
- a generation of a time-enhancement curve may not be necessary and therefore in these examples a time resolved sequencing of the set of corresponding images also becomes optional; more specifically, a set of corresponding images may be queried to identify and select an image with peak signal intensity and extract a peak enhancement value without establishing a time- enhancement curve.
- a blood flow characteristic may be any metric that assesses blood flow at a region of interest in a subject.
- a blood flow characteristic includes, for example, flow rate, flow velocity and flow pressure. Rate, velocity, and pressure are metrics of blood flow.
- FFR is another metric.
- Shear stress is another metric. Area under the curve, rate of change of area under the curve, peak (maximum value) of the curve, and blood volume may be considered as further examples of a blood flow characteristic. Examples of calculations to determine flow rate, flow velocity, flow pressure, FFR and shear stress are provided in the Mathematical Analysis section.
- FIG. 20 Benefit of determining area under the curve (AUC), rate of change of area under the curve and peak of the curve is evident from Figure 20.
- Figure 20 further shows that the time-enhancement curve itself is indicative of blood flow at a sampling site, and therefore the time-enhancement curve itself can be considered a blood flow characteristic.
- Additional metrics of area under curve (AUC), peak enhancement (PE), upslope, downslope, skewness, and kurtosis as derived from time-enhancement curves are illustrated in Tables 6-9.
- Assessment of blood flow and determination of a blood flow characteristic can provide a diagnostic result. For example, determining time-enchancement curves at first and second sampling sites yields a first time-enhancement curve and a second time-enhancement curve; and estimating of the blood flow characteristic comprises a determination including corresponding values calculated from the first and second time-enhancement curves.
- the blood flow characteristic value may in itself provide a diagnostic result.
- corresponding values calculated from the first and second time-enhancement curves are compared and a difference in the corresponding values beyond a predetermined threshold is indicative of a diagnostic result. Thresholds and corresponding diagnostic results can be adopted from relevant literature and medical guidelines.
- 0.8 is considered normal and below 0.8 is indicative that a stenosis may have functional significance.
- various correlations of metrics, thresholds and diagnostic results may be developed.
- a region of interest is an area on a digital image that circumscribes or encompasses a desired anatomical location, for example a blood vessel of interest or a portion of a blood vessel of interest.
- Image processing systems permit extraction of data from ROI on images, including for example an average parametric value computed for all pixels within the ROI.
- a sampling site is the location of one or more imaging slices selected to assess a desired anatomical location, such as a blood vessel of interest. ROI may be used interchangeably with sampling site, when the sampling site is at or near the ROI. In some examples, analysis of a time-enhancement curve from a single sampling site may be sufficient to determine a blood flow characteristic or metric.
- a plurality of sampling sites, or a plurality imaging slices may be analyzed to obtain a plurality of corresponding image sets and to generate a plurality of corresponding time- enhancement curves, and any number of the plurality of corresponding time-enhancement curves may be compared to determine a blood flow characteristic or blood flow metric.
- Conventional scanners can capture 3D image data for all or part of a blood vessel of interest, and possibly even all or parts of a plurality of blood vessels of interest.
- a scan can be subdivided into a plurality of slices as desired, and therefore interrogation of multiple sites or slices at an ROI, near an ROI, upstream of an ROI, downstream of any ROI, or any combination thereof, is feasible and convenient.
- multi-slice or multi-site imaging modalities may simultaneous tomographic slices or sampling sites may be extracted per scan.
- the DAI method need not be limited to analysis of one or two time-enhancement curves for a scan of a contrast agent transit (entry to clearance) at blood vessel interest and a single scanning procedure with a single bolus injection of contrast agent can support a plurality of slices or sampling sites divided from the scan data as desired.
- a blood vessel of interest may be any blood vessel that can be imaged by a contrast- enhanced imaging technique.
- the blood vessel of interest will typically have a diameter of at least about 0.1 mm, for example a diameter greater than 0.2 mm or a diameter greater than 0.3 mm.
- the blood vessel of interest or a designated portion of the blood vessel of interest may be identified and targeted for contrast enhanced dynamic angiographic imaging to determine a diagnosis of a blood vessel disorder or to determine a predisposition to a blood vessel disorder.
- the blood vessel of interest can be within any anatomical area or any organ (for example, brain, lung, heart, liver, kidney and the like) in an animal body (for example, a human body).
- the DAI method is not limited to scan data acquired while a subject is in a hyperemic state (also referred to as hyperemic stress or vasodilatory stress) and time-enhancement curves generated from scan data acquired while a subject is in a non-hyperemic state (also referred to as a resting state) can produce a useful result. Examples of useful time-enhancement curves generated from scan data acquired from a subject in a resting state are shown in Figures 25 to 27.
- a blood flow characteristic will be analyzed based on at least one time-enhancement curve, including for example a single time-enhancement curve generated from a scan of a single sampling site, or as another example a plurality of time-enhancement curves respectively generated from a corresponding plurality of sampling sites.
- a comparison of two sampling sites is beneficial to compare a blood flow characteristic determined at a sampling site upstream of the stenosis with a blood flow characteristic determined at a sampling site downstream of the stenosis.
- FFR by definition (see Equation 9) can be considered a flow pressure ratio with a flow pressure determined downstream of stenosis as numerator and a flow pressure determined upstream of stenosis as denominator.
- a plurality of sampling sites may be designated at or near the blood vessel of interest; a time- enhancement curve generated for each of the plurality of sampling sites; a desired blood flow characteristic based on a respective time-enhancement curve determined for each of the plurality of sampling sites; and comparing the determined blood flow characteristic of each of the plurality of sampling sites to determine a blood vessel disorder.
- Figure 20a shows that comparison of the time-enhancement curves generated at a plurality of sampling sites at or near the blood vessel of interest is effective to determine a presence or absence of a blood vessel disorder.
- determining of a blood flow characteristic at one or more sampling sites or determining presence of absence of a blood vessel disorder based on a comparison of blood flow characteristic at a plurality of sampling sites can provide a diagnostic result.
- the DAI method does not require the scanned subject or patient to hold breath during a scan procedure. Breath-hold is an option in some examples. In other examples, motion correction or motion compensation processing of image data may be used for scan data acquired without breath- hold of the subject or patient.
- Embodiments disclosed herein, or portions thereof, can be implemented by programming one or more computer systems or devices with computer-executable instructions embodied in a non-transitory computer-readable medium. When executed by a processor, these instructions operate to cause these computer systems and devices to perform one or more functions particular to embodiments disclosed herein. Programming techniques, computer languages, devices, and computer-readable media necessary to accomplish this are known in the art.
- a non-transitory computer readable medium embodying a computer program for dynamic angiographic imaging may comprise: computer program code for obtaining image data comprising a plurality of corresponding images capturing at least a portion of both an increase phase and a decline phase of a contrast agent in a blood vessel of interest; computer program code for generating at least one time-enhancement curve of the contrast agent based on the image data, the time-enhancement curve having an upslope and a downslope; and computer program code for determining a blood flow characteristic in the blood vessel of interest based on the time- enhancement curve.
- the image data comprises at least one image capturing the blood vessel of interest prior to entry of the contrast agent.
- the computer readable medium further comprises computer program code for determining a reference value based on the at least one image capturing the blood vessel of interest prior to entry of the contrast agent, and normalizing the time-enhancement curve based on the reference value.
- the computer readable medium further comprises computer program code for acquiring scan data of the blood vessel of interest from a X-ray based scan or a MRI scan, and reconstructing image data based on the scan data.
- the computer readable medium is a data storage device that can store data, which can thereafter, be read by a computer system.
- Examples of a computer readable medium include read only memory, random-access memory, CD-ROMs, magnetic tape, optical data storage devices and the like.
- the computer readable medium may be geographically localized or may be distributed over a network coupled computer system so that the computer readable code is stored and executed in a distributed fashion.
- Computer-implementation of the system or method typically comprises a memory, an interface and a processor.
- the interface may include a software interface that communicates with an end-user computing device through an Internet connection.
- the interface may also include a physical electronic device configured to receive requests or queries from a device sending digital and/or analog information.
- the interface can include a physical electronic device configured to receive signals and/or data relating to the DAI method and system, for example from an imaging scanner or image processing device.
- Any suitable processor type may be used depending on a specific implementation, including for example, a microprocessor, a programmable logic controller or a field programmable logic array.
- any conventional computer architecture may be used for computer- implementation of the system or method including for example a memory, a mass storage device, a processor (CPU), a Read-Only Memory (ROM), and a Random-Access Memory (RAM) generally connected to a system bus of data-processing apparatus.
- Memory can be implemented as a ROM, RAM, a combination thereof, or simply a general memory unit.
- Software modules in the form of routines and/or subroutines for carrying out features of the system or method can be stored within memory and then retrieved and processed via processor to perform a particular task or function.
- one or more method steps may be encoded as a program component, stored as executable instructions within memory and then retrieved and processed via a processor.
- a user input device such as a keyboard, mouse, or another pointing device, can be connected to PCI (Peripheral Component Interconnect) bus.
- the software may provide an environment that represents programs, files, options, and so forth by means of graphically displayed icons, menus, and dialog boxes on a computer monitor screen. For example, any number of blood flow images and blood flow characteristics may be displayed, including for example a time-enhancement curve.
- Computer-implementation of the system or method may accommodate any type of end-user computing device including computing devices communicating over a networked connection.
- the computing device may display graphical interface elements for performing the various functions of the system or method, including for example display of a blood flow characteristic determined for a blood vessel of interest.
- the computing device may be a server, desktop, laptop, notebook, tablet, personal digital assistant (PDA), PDA phone or smartphone, and the like.
- PDA personal digital assistant
- the computing device may be implemented using any appropriate combination of hardware and/or software configured for wired and/or wireless communication. Communication can occur over a network, for example, where remote control of the system is desired.
- the system or method may accommodate any type of network.
- the network may be a single network or a combination of multiple networks.
- the network may include the internet and/or one or more intranets, landline networks, wireless networks, and/or other appropriate types of communication networks.
- the network may comprise a wireless telecommunications network (e.g., cellular phone network) adapted to communicate with other communication networks, such as the Internet.
- the network may comprise a computer network that makes use of a TCP/IP protocol (including protocols based on TCP/IP protocol, such as HTTP, HTTPS or FTP).
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medical Informatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- Radiology & Medical Imaging (AREA)
- Surgery (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- High Energy & Nuclear Physics (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Primary Health Care (AREA)
- Physiology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Databases & Information Systems (AREA)
- Data Mining & Analysis (AREA)
- Pulmonology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Dentistry (AREA)
- Theoretical Computer Science (AREA)
- Signal Processing (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- General Physics & Mathematics (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Urology & Nephrology (AREA)
- Apparatus For Radiation Diagnosis (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Image Analysis (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020563678A JP7481264B2 (en) | 2018-05-17 | 2019-05-16 | Dynamic Angiographic Imaging |
EP19803277.3A EP3793432A4 (en) | 2018-05-17 | 2019-05-16 | Dynamic angiographic imaging |
CN201980046802.7A CN112423660A (en) | 2018-05-17 | 2019-05-16 | Dynamic angiographic imaging |
CA3100421A CA3100421A1 (en) | 2018-05-17 | 2019-05-16 | Dynamic angiographic imaging |
KR1020207035523A KR20210010880A (en) | 2018-05-17 | 2019-05-16 | Dynamic angiography imaging |
US17/055,784 US20210228171A1 (en) | 2018-05-17 | 2019-05-16 | Dynamic angiographic imaging |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862672896P | 2018-05-17 | 2018-05-17 | |
US62/672,896 | 2018-05-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2019218076A1 true WO2019218076A1 (en) | 2019-11-21 |
Family
ID=68541103
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA2019/050668 WO2019218076A1 (en) | 2018-05-17 | 2019-05-16 | Dynamic angiographic imaging |
Country Status (7)
Country | Link |
---|---|
US (1) | US20210228171A1 (en) |
EP (1) | EP3793432A4 (en) |
JP (1) | JP7481264B2 (en) |
KR (1) | KR20210010880A (en) |
CN (1) | CN112423660A (en) |
CA (1) | CA3100421A1 (en) |
WO (1) | WO2019218076A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20220110530A2 (en) * | 2019-12-09 | 2022-04-14 | Nordsletten David | Method and System for Estimating Pressure Difference in Turbulent Flow |
US11950893B2 (en) * | 2020-01-17 | 2024-04-09 | The Research Foundation For The State University Of New York | Apparatus and method of determining dynamic vascular parameters of blood flow |
US20230076477A1 (en) * | 2021-09-05 | 2023-03-09 | Shimadzu Corporation | Imaging device and imaging method |
CN116564525B (en) * | 2023-07-10 | 2023-09-26 | 天津恒宇医疗科技有限公司 | Fractional flow reserve prediction method and system based on coronary blood flow distribution |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6745066B1 (en) * | 2001-11-21 | 2004-06-01 | Koninklijke Philips Electronics, N.V. | Measurements with CT perfusion |
WO2005044104A1 (en) * | 2003-11-06 | 2005-05-19 | Mie Tlo Co., Ltd. | Method of quantifying blood flow through heart muscle |
US20140114185A1 (en) * | 2012-06-26 | 2014-04-24 | Sync-Rx, Ltd. | Determining a characteristic of a lumen by measuring temporal changes in contrast agent density |
US8929632B2 (en) * | 2011-09-22 | 2015-01-06 | Siemens Aktiengesellschaft | Temporal difference encoding for angiographic image sequences |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8326400B2 (en) * | 2004-05-04 | 2012-12-04 | Stiftelsen Universitetsforskning Bergen | Method of MR imaging |
US7974682B2 (en) * | 2006-11-22 | 2011-07-05 | Marcela Gonzalez Molezzi | System and method to adaptively control contrast-enhanced diagnostic imaging procedure |
US11064964B2 (en) * | 2007-03-08 | 2021-07-20 | Sync-Rx, Ltd | Determining a characteristic of a lumen by measuring velocity of a contrast agent |
JP5361410B2 (en) * | 2009-01-22 | 2013-12-04 | 株式会社東芝 | Image processing device |
US9174065B2 (en) * | 2009-10-12 | 2015-11-03 | Kona Medical, Inc. | Energetic modulation of nerves |
DE102010062030A1 (en) * | 2010-11-26 | 2012-05-31 | Siemens Aktiengesellschaft | Method for calculating perfusion data from 2-D angiography data or DSA sequences |
US20130172734A1 (en) * | 2011-12-30 | 2013-07-04 | General Electric Company | Flow measurement with time-resolved data |
WO2013183775A1 (en) * | 2012-06-07 | 2013-12-12 | 株式会社東芝 | Image processing device and x-ray diagnostic device |
US20140086461A1 (en) * | 2012-09-25 | 2014-03-27 | The Johns Hopkins University | Method and system for determining time-based index for blood circulation from angiographic imaging data |
WO2015041312A1 (en) * | 2013-09-20 | 2015-03-26 | 国立大学法人旭川医科大学 | Method and system for image processing of intravascular hemodynamics |
NL2012459B1 (en) * | 2014-03-18 | 2016-01-08 | Medis Ass B V | Method and device for determining deviation in pressure in a blood vessel. |
US9517042B2 (en) * | 2014-09-12 | 2016-12-13 | General Electric Company | Systems and methods for imaging phase selection for computed tomography imaging |
US11141123B2 (en) | 2014-12-02 | 2021-10-12 | Koninklijke Philips N.V. | Fractional flow reserve determination |
CN104688259B (en) * | 2015-02-16 | 2018-01-09 | 袁小东 | CT scan method for filling and device |
CN105326486B (en) * | 2015-12-08 | 2017-08-25 | 博动医学影像科技(上海)有限公司 | Vascular pressure difference and the computational methods and system of blood flow reserve fraction |
-
2019
- 2019-05-16 EP EP19803277.3A patent/EP3793432A4/en active Pending
- 2019-05-16 WO PCT/CA2019/050668 patent/WO2019218076A1/en active Application Filing
- 2019-05-16 CN CN201980046802.7A patent/CN112423660A/en active Pending
- 2019-05-16 US US17/055,784 patent/US20210228171A1/en active Pending
- 2019-05-16 KR KR1020207035523A patent/KR20210010880A/en not_active Application Discontinuation
- 2019-05-16 JP JP2020563678A patent/JP7481264B2/en active Active
- 2019-05-16 CA CA3100421A patent/CA3100421A1/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6745066B1 (en) * | 2001-11-21 | 2004-06-01 | Koninklijke Philips Electronics, N.V. | Measurements with CT perfusion |
WO2005044104A1 (en) * | 2003-11-06 | 2005-05-19 | Mie Tlo Co., Ltd. | Method of quantifying blood flow through heart muscle |
US8929632B2 (en) * | 2011-09-22 | 2015-01-06 | Siemens Aktiengesellschaft | Temporal difference encoding for angiographic image sequences |
US20140114185A1 (en) * | 2012-06-26 | 2014-04-24 | Sync-Rx, Ltd. | Determining a characteristic of a lumen by measuring temporal changes in contrast agent density |
Non-Patent Citations (1)
Title |
---|
See also references of EP3793432A4 * |
Also Published As
Publication number | Publication date |
---|---|
EP3793432A1 (en) | 2021-03-24 |
JP7481264B2 (en) | 2024-05-10 |
JP2021522941A (en) | 2021-09-02 |
CN112423660A (en) | 2021-02-26 |
EP3793432A4 (en) | 2022-03-23 |
KR20210010880A (en) | 2021-01-28 |
US20210228171A1 (en) | 2021-07-29 |
CA3100421A1 (en) | 2019-11-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10803994B2 (en) | Vascular flow assessment | |
JP7481264B2 (en) | Dynamic Angiographic Imaging | |
JPH11151224A (en) | Photographic device for angiogram | |
KR102402628B1 (en) | Methods and systems for modeling the human heart and atria | |
US20170325770A1 (en) | Methods for personalizing blood flow models | |
WO2021141135A1 (en) | Functional ischemia detection technique by coronary artery ct4d flow imaging | |
JP6133794B2 (en) | Dynamic normalization of data for perfusion comparison and quantification. | |
US20170325769A1 (en) | Methods for personalizing blood flow models | |
US20180092615A1 (en) | Medical information processing apparatus, x-ray ct apparatus, and medical information processing method | |
JP2022552341A (en) | Perfusion angiography combined with photoplethysmographic imaging for determination of peripheral vascular disease. | |
CN109688908A (en) | Device and method for determining blood flow reserve score | |
US11406339B2 (en) | System and method for determining vascular velocity using medical imaging | |
US10201321B2 (en) | Low-dose CT perfusion technique | |
JP2018057835A (en) | Medical information processing apparatus, x-ray ct apparatus, and medical information processing program | |
JP6449675B2 (en) | Nuclear medicine test method to calculate an index to predict partial coronary flow reserve | |
US20230346330A1 (en) | Blood flow imaging | |
US20240104728A1 (en) | Providing a result dataset | |
Tache | Statistical Evaluation of Velocity Estimations from Temporal Fluoroscopic Angiography | |
Tache et al. | Transit time estimations from coronary angiograms | |
Cai et al. | Multiparametric evaluation of the degree of hindlimb ischemia with mathematical model and hemodynamics of ICG | |
Ritman | Three-dimensional reconstruction of the coronary arterial tree geometry--rationale and recent progress |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19803277 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2020563678 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 3100421 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20207035523 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2019803277 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2019803277 Country of ref document: EP Effective date: 20201217 |